Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VE-BASKET: Vemurafenib in BRAF V600+ Cancers
NCT01524978Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2012
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of vemurafenib in non-small cell lung cancer (NSCLC), ovarian cancer, colorectal cancer (CRC), cholangiocarcinoma (CCA), multiple myeloma (MM), sponsored by Roche. Started Apr 2012; status: completed.
02
Drugs
vemurafenib
03
Conditions
non-small cell lung cancer (NSCLC)ovarian cancercolorectal cancer (CRC)cholangiocarcinoma (CCA)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01524978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01524978.